PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutant p53-carrying tumors are often more resistant to chemotherapeutical drugs. We demonstrate here that the mutant p53-reactivating compound PRIMA-1(MET) acts synergistically with several chemotherapeutic drugs to inhibit tumor cell growth. Combined treatment with cisplatin and PRIMA-1(MET) resulted in a synergistic induction of tumor cell apoptosis and inhibition of human tumor xenograft growth in vivo in SCID mice. The induction of mutant p53 levels by chemotherapeutic drugs is likely to increase the sensitivity of tumor cells to PRIMA-1(MET). Thus, the combination of PRIMA-1(MET) with currently used chemotherapeutic drugs may represent a novel and more efficient therapeutic strategy for treatment of mutant p53-carrying tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (15,19–22). Whereas HEY-CTLshRNA cells were practically insensitive to APR-246, HEY-CIP2AshRNA cells showed a >50% reduction in cell viability (Fig. 1A).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [15]
In the citing paper
“The small molecule APR-246 (PRIMA-1Met) can reactive mutant p53 in tumor cells and trigger cell death by apoptosis.”
From Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246 (2018) · cites this paper as [7]
In the citing paper
“Importantly, PRIMA-1 and its structural analog PRIMA-1MET (APR-246) inhibited tumor growth in mouse models of GBM [124,129,130].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [129]
In the citing paper
“Although APR-246 was originally identified as a compound that reactivates mutant TP53 (15,16,20), the tested OvCa cell lines displaying hypersensitivity to APR-246 upon CIP2A inhibition, exhibit varying TP53 mutation statuses.”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
In the citing paper
“The most apparent sensitization effect was observed with APR-246 (PRIMA-1Met/Eprenetapopt) (14)(15)(16)(17)(18).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [15]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · cited 1×
“In addition, p53 can transrepress some genes, for instance the antiapoptotic Bcl-2 gene, the IGF1 receptor, MAP4, and hTERT (Vogelstein et al., 2000).”
BackgroundLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192 · cited 1×
“…protein induces cell cycle arrest and/or cell death by apoptosis in response to various forms of cellular stress, for example, DNA damage and oncogene activation (Vousden and Lu, 2002). p53 elicits these responses through transcriptional regulation of a large number of downstream effector genes.”
BackgroundAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L. V., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183 · cited 1×
“Likewise, several clinical studies have indicated that anticancer drugs preferentially target wild-type p53carrying breast tumors (Bergh et al., 1995; O’Connor et al., 1997; Weinstein et al., 1997; Borresen-Dale, 2003).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“Our previous studies indicated that tumor cells expressing high levels of mutant p53 are more sensitive to PRIMA-1 (Bykov et al., 2002a).”
BackgroundInfluentialSelf-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“Studies in cultured human tumor cells and various mouse tumor models have shown that inactivation of p53 reduces or abrogates the apoptotic response to chemotherapy (Bunz et al., 1999; Keshelava et al., 2001; Schmitt, 2003).”
BackgroundPharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799 · cited 9×
“Interestingly, CP-31398 that was shown to induce p53 levels through inhibition of p53 ubiquitination (Wang et al., 2003) induced mutant p53 levels and phosphorylation of p53 at Ser15 in H1299-His175 cells and showed synergy with PRIMA-1MET in mutant p53-expressing cells.”
BackgroundInfluentialThe p53–Mdm2 module and the ubiquitin system
Michael, D., & Oren, M. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00099-8 · Cited by 765 · cited 1×
“The p53-induced MDM2 gene regulates p53 turnover via a negative feedback loop that ensures low levels of p53 in the absence of stress signaling (Michael and Oren, 2003).”
BackgroundBergh, J., Norberg, T., Sjögren, S., Lindgren, A., & Holmberg, L. (1995) · Nature Medicine · doi:10.1038/nm1095-1029 · Cited by 460
Chemosensitivity linked to p73 function
Irwin, M. S., Kondo, K., Marin, M. C., Cheng, L. S., Hahn, W. C., & Kaelin, W. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00078-3 · Cited by 408 · cited 1×
“Cisplatin has been shown to induce p73-dependent apoptosis (Irwin et al., 2003).”
BackgroundBørresen-Dale, A.-L. (2003) · Human Mutation · doi:10.1002/humu.10174 · Cited by 354
Cited by
Items 201–255 of 255
PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells
Piyawajanusorn, C., Kittirat, Y., Sa-Ngiamwibool, P., Titapun, A., Loilome, W., & Namwat, N. (2019) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20156 · Cited by 7
A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
Zhang, B., Zhang, H., & Qin, Y. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25447 · Cited by 8
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0622 · Cited by 5
Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5
Naeimzadeh, Y., Tajbakhsh, A., & Fallahi, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26260 · Cited by 5
“Noteworthy, APR-246 has more pro-apoptotic potency than PRIMA-1 and is known as the most investigated and advanced clinically mutant p53 reactivating compound [44,127,130].”
BackgroundPestones A and B from a Fungus Pestalotiopsis sp. Bound to Mutant p53 and Changed Its Conformation
Sadahiro, Y., Okubo, M., Hitora, Y., HitoraーImamura, N., Kotani, S., & Tsukamoto, S. (2025) · Journal of Natural Products · doi:10.1021/acs.jnatprod.4c01440 · Cited by 5
Khadiullina, R., Chasov, V., Gilyazova, E., Davletshin, D., Mirgayazova, R., Mingaleeva, R. N., Clarke, J. R. S., Baud, M. G. J., & Bulatov, E. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02781-6 · Cited by 4
[P53 and its role in the ovarian surface epithelium. A review].
Chuaire, L., Sánchez, M. C., & Ramírez-Clavijo, S. R. (2008) · PubMed · Cited by 9
Relative Stability of Wild-Type and Mutant p53 Core Domain: A Molecular Dynamic Study
Rohani, L., Morton, D. J., Wang, X., & Chaudhary, J. (2015) · Journal of Computational Biology · doi:10.1089/cmb.2015.0163 · Cited by 4
Han, X., Du, J., Shi, D., Li, L., Li, D., Zhang, K., Lin, S.-W., Zhu, J., Huang, Z., Zhou, Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213867 · Cited by 3
Regulation of p53 Activity and Associated Checkpoint Controls
Post, S. M., Quintás‐Cardama, A., & Lozano, G. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-178-3_11 · Cited by 2
Mutant p53 Reactivation as a Novel Strategy for Cancer Therapy
Selivanova, G., Bykov, V. J. N., & Wiman, K. G. (2005) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_18 · Cited by 3
Self-citationTargeting TP53 to augment therapeutic response in head and neck cancer
Osman, A. A., Lindemann, A., Wang, L., Frank, S. J., & Myers, J. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-817868-3.00004-4 · Cited by 3
MicroRNA-29a plays a prominent role in PRIMA-1Met-induced apoptosis in ovarian cancer cells
İmir, N. (2020) · Archives of Biological Sciences · doi:10.2298/abs191128011i · Cited by 1
“PRIMA-1Met was shown to inhibit cell proliferation and to induce apoptosis in malignant cell cultures containing different p53 mutations and in some xenograft animal tumors by restoration of the p53 tumor suppressor function [12-16].”
BackgroundCellular signaling in glioblastoma: A molecular and clinical perspective
Ghosh, D., Pryor, B., & Jiang, N. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.007 · Cited by 2
Curylova, L., Zambo, I. S., Neradil, J., Kýr, M., Jurackova, N., Pavlová, Š., Polášková, K., Múdrý, P., Štěrba, J., Veselská, R., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01020-x · Cited by 1
Li, X., Zhou, J., Tang, N. X., Chai, Y. X., Zhou, M., Gao, A., Lu, Z., & Min, H. (2025) · Cancer Medicine · doi:10.1002/cam4.70530 · Cited by 5
Drugging p53 mutants: Recent advances using small-molecule modulation strategies
Lopes, E. A., Monteiro, T. G., & Santos, M. M. M. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119149 · Cited by 2
Celesia, A., Piccoli, F., Wang, T., Hu, Y., Danzi, F., Aparo, A., Cisterna, B., Pacchiana, R., Poles, M., Scupoli, M. T., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02746-y · Cited by 1
Poulsen, K. X. H. S. (2011) · Journal of Clinical & Experimental Pathology · doi:10.4172/2161-0681.s5-001 · Cited by 1
Research Progress of Mutant p53 as a Potential Therapeutic Target for Breast Cancer
周, 俊. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111807 · Cited by 1
Role of TP53 Mutations in Cancer (An Overview)
Toledo, F. (2008) · Springer eBooks · doi:10.1007/978-1-4020-8442-3_5 · Cited by 2
Natarajan, A., Babikir, H. A., Paulmurugan, R., & Massoud, T. F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821567-8.00017-8 · Cited by 1
Cancer Therapy by Reactivation of the p53 Apoptosis Pathway
Stridh, H., Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2006) · Wiley eBooks · doi:10.1002/9783527619665.ch35 · Cited by 1
Self-citationGenomic Mutation as A Potential Driver of The Development of Bone-Related Cancers
Park, S. H., & Shiozawa, Y. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11452-7 · Cited by 1
Role of integrin signaling in cell proliferation and survival
Bao, W. (2005) · Figshare
TP53 mutations in myelodysplastic syndromes with deletion of 5q
Saft, L. (2013) · Figshare
Piantino, C. B. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2012.tde-25092012-090310
Restoring p53 Function: Novel Anticancer Approaches for an Old Foe
(2012) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608054787112010010 · Cited by 1
“PRIMA-1 has demonstrated synergistic antitumor effects in combination with cytotoxic drugs, such as cisplatin and 5-FU, exclusively in cells expressing mutant p53 [74] (Table 4).”
BackgroundStudies of mutant p53-targeting small molecules
Zache, N. (2007) · Figshare
Self-citationInduction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-xL
Rossi, M., Bang, J.-K., Mazur, S. J., Iera, J. A., Phillips, D. C., Zambetti, G. P., & Appella, D. H. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.03.067
DNA damage-induced cell death : The role of caspase-2
Vakifahmetoglu, H. (2009) · Figshare
Pharmacological targeting of mutant p53 family members
Rökaeus, N. (2011) · Figshare
Targeting Mutant p53 for Improved Cancer Therapy
Shen, J., Bykov, V. J. N., & Wiman, K. G. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_14
Self-citationRôle de deux suppresseurs de tumeurs TET2 et P53 dans un contexte hématopoïétique
Mahfoudhi, E. (2016) · theses.fr (ABES) · doi:10.70675/f4cb068cz8085z4a5az9d43z0a573a109bcb
ID4 Acts as a Tumor Suppressor via p53: Mechanistic Insight
Morton, & Derrick, J. P. (2016) · Atlanta University Center Robert W. Woodruff Library (Atlanta University Center Robert W. Woodruff Library)
p53 Tumor Suppressor Opens Gateways for Cancer Therapy
Dai, M., Gallegos, J. R., & Lu, H. (2008) · CRC Press eBooks · doi:10.1201/9780849387999.ch48
Investigation of novel therapeutic strategies for epithelial ovarian cancer
Yoshikawa, N. (2016) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
An investigation of mutant p53 function.
Noll, J. E. (2011) · Adelaide Research & Scholarship (AR&S) (University of Adelaide)
Understanding p53 structure and targeting mutant p53 for improved cancer therapy
Zhang, Q. (2018) · Figshare
Making sense from nonsense and missense : pharmacological rescue of mutant tumor suppressor p53
Zhang, M. (2018) · Figshare
Increasing Chemosensitivity in Colorectal Cancer
Agro, L. A. (2019) · TSpace (University of Toronto)
OVER KANSERİ HÜCRELERİNDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİŞEN miRNA EKSPRESYON ANALİZİ
İmir, N., Aydemir, E. A., & Şimşek, E. (2020) · Sağlık Bilimleri Dergisi · doi:10.34108/eujhs.543409
Effect of stress during neutron irradiation on the microstructure of type 316 stainless steel
Brager, H. R., Garner, F. A., & Guthrie, G. L. (1976) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)
Targeting MDM2, the antagonist of the tumor suppressor p53
Sriraman, A. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7056 · Cited by 2
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H. J., Bützow, R. C., Haglund, C. H., Kaipio, K., Arsiola, T., et al. (2023) · doi:10.1158/1535-7163.c.6543912
de Bakker, T., Cogels, M., Iliadi, C., Penninckx, S., Martinive, P., & Gestel, D. V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.23.630069 · Cited by 1
A dual-action liposome-peptide formulation synergistically counteracts a gain-of-function p53 mutant
Chaudhary, S. G., Bhowmick, S., Bhattacharya, S., Roy, S., & Ali, N. (2025) · Journal of Liposome Research · doi:10.1080/08982104.2025.2555179
Targeting transcription factors in cancers
Hu, L., Zhang, J., & Wu, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00043-1
Targeting the p53/MDM2 Pathway for Cancer Therapy
Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2
Rôle des mastocytes dans le développement des astrocytomes humains : implication du récepteur CD47
Boukhari, A. A. (2012) · theses.fr (ABES) · doi:10.70675/3c922fc3z5510z47b6zba8ezeb4143cfb7ba
Etude de la ferroptose dans les leucémies aiguës myéloïdes : nouvelles stratégies thérapeutiques
Birsen, R. (2020) · theses.fr (ABES) · doi:10.70675/45ca3261z22a8z4237z8076zf98342173232
Marret, G. (2023) · theses.fr (ABES) · doi:10.70675/fe5bbd3fzfc82z43ffz9c6dzf2c8d40c19dd
Wang, L., & Chen, C. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100960
Metadata
- Authors
- Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G.
- Affiliations
- Karolinska Institutet (SE)
- Corresponding author
- Wiman, Klas G
- Venue
- Oncogene
- Published
- 2005-02-28
- Volume
- 24
- Issue
- 21
- Pages
- 3484-3491
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2006422601
- Cited by
- 252
- References
- 19
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 16 · 2021: 21 · 2020: 14 · 2019: 12 · 2018: 18 · 2017: 7 · 2016: 16 · 2015: 11 · 2014: 7 · 2013: 9 · 2012: 11
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancerfonden
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- mutant p53 reactivation, cisplatin, drug synergy, apoptosis, chemoresistance, combination chemotherapy, xenograft tumor growth, SCID mice
- MeSH terms
- Adenocarcinoma, Animals, Aza Compounds, Bone Neoplasms, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Interactions, Humans, Lung Neoplasms, Mutation, Quinuclidines, Osteosarcoma, Transplantation, Heterologous, Tumor Cells, Cultured, Genes, p53, Mice, SCID, Apoptosis, Drug Resistance, Neoplasm, Bridged Bicyclo Compounds, Heterocyclic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.